136 related articles for article (PubMed ID: 3349561)
1. Pharmacokinetics of Amonafide in dogs.
Lu K; McLean MA; Vestal ML; Newman RA
Cancer Chemother Pharmacol; 1988; 21(2):134-8. PubMed ID: 3349561
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and metabolism of the antitumor drug amonafide (NSC-308847) in humans.
Felder TB; McLean MA; Vestal ML; Lu K; Farquhar D; Legha SS; Shah R; Newman RA
Drug Metab Dispos; 1987; 15(6):773-8. PubMed ID: 2893701
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical investigation of amonafide.
Saez R; Craig JB; Kuhn JG; Weiss GR; Koeller J; Phillips J; Havlin K; Harman G; Hardy J; Melink TJ
J Clin Oncol; 1989 Sep; 7(9):1351-8. PubMed ID: 2549205
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia.
O'Brien S; Benvenuto JA; Estey E; Beran M; Felder TB; Keating M
Cancer Res; 1991 Feb; 51(3):935-8. PubMed ID: 1988134
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of homoharringtonine in dogs.
Lu K; Savaraj N; Feun LG; Guo ZG; Umsawasdi T; Loo TL
Cancer Chemother Pharmacol; 1988; 21(2):139-42. PubMed ID: 3349562
[TBL] [Abstract][Full Text] [Related]
6. Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).
Costanza ME; Berry D; Henderson IC; Ratain MJ; Wu K; Shapiro C; Duggan D; Kalra J; Berkowitz I; Lyss AP
Clin Cancer Res; 1995 Jul; 1(7):699-704. PubMed ID: 9816035
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic characterization of mitonafide in man.
Brode E; Poveda Velasco A; Díaz-Rubio E; Rosell Costa R; Benavides Fissure A
Methods Find Exp Clin Pharmacol; 1992 Mar; 14(2):131-40. PubMed ID: 1598025
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of amonafide dosing based on acetylator phenotype.
Ratain MJ; Mick R; Berezin F; Janisch L; Schilsky RL; Vogelzang NJ; Lane LB
Cancer Res; 1993 May; 53(10 Suppl):2304-8. PubMed ID: 8485716
[TBL] [Abstract][Full Text] [Related]
9. Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender.
Ratain MJ; Mick R; Janisch L; Berezin F; Schilsky RL; Vogelzang NJ; Kut M
Pharmacogenetics; 1996 Feb; 6(1):93-101. PubMed ID: 8845865
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study.
Ratain MJ; Rosner G; Allen SL; Costanza M; Van Echo DA; Henderson IC; Schilsky RL
J Clin Oncol; 1995 Mar; 13(3):741-7. PubMed ID: 7884434
[TBL] [Abstract][Full Text] [Related]
11. Paradoxical relationship between acetylator phenotype and amonafide toxicity.
Ratain MJ; Mick R; Berezin F; Janisch L; Schilsky RL; Williams SF; Smiddy J
Clin Pharmacol Ther; 1991 Nov; 50(5 Pt 1):573-9. PubMed ID: 1934870
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacokinetics of amonafide (NSC 308847) in 62 patients.
Kreis W; Chan K; Budman DR; Allen SL; Fusco D; Mittelman A; Hock K; Akerman S; Calabro A; Puccio C; Spigelman M
Cancer Invest; 1996; 14(4):320-7. PubMed ID: 8689426
[TBL] [Abstract][Full Text] [Related]
13. Qualitative and quantitative determination of two new antitumor agents from 1-8 naphthalimides in tablets. Validation of a high performance liquid chromatography method.
Camacho MA; Torres AI; Gil ME; Obregón MM; Ruz V
Arzneimittelforschung; 1994 May; 44(5):659-62. PubMed ID: 8024643
[TBL] [Abstract][Full Text] [Related]
14. An ECOG phase II study of amonafide in unresectable or recurrent carcinoma of the head and neck (PB390). Eastern Cooperative Oncology Group.
Leaf AN; Neuberg D; Schwartz EL; Wadler S; Ritch PS; Dutcher JP; Adams GL
Invest New Drugs; 1997; 15(2):165-72. PubMed ID: 9220297
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of amonafide in central nervous system tumors: a Southwest Oncology Group study.
Taylor SA; Rankin C; Townsend JJ; Craig JB; Vance RB; Solank DL; Brown TD; Jaeckle K;
Invest New Drugs; 2002 Feb; 20(1):113-5. PubMed ID: 12003186
[TBL] [Abstract][Full Text] [Related]
16. Correspondence re: Mark J. Ratain et al., Limited Sampling Models for Amonafide (NSC 308847) Pharmacokinetics.
Lemmer B
Cancer Res; 1989 Jun; 49(11):3139-40. PubMed ID: 2720672
[No Abstract] [Full Text] [Related]
17. Phase II study of amonafide in advanced breast cancer.
Scheithauer W; Dittrich C; Kornek G; Haider K; Linkesch W; Gisslinger H; Depisch D
Breast Cancer Res Treat; 1991 Dec; 20(1):63-7. PubMed ID: 1813070
[TBL] [Abstract][Full Text] [Related]
18. Limited sampling models for amonafide (NSC 308847) pharmacokinetics.
Ratain MJ; Staubus AE; Schilsky RL; Malspeis L
Cancer Res; 1988 Jul; 48(14):4127-30. PubMed ID: 3383202
[TBL] [Abstract][Full Text] [Related]
19. The pharmacologic fate of the antitumor agent 2-amino-1,3,4-thiadiazole in the dog.
Lu K; Loo TL
Cancer Chemother Pharmacol; 1980; 4(4):275-9. PubMed ID: 7438330
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of michellamine B, a naphthylisoquinoline alkaloid with in vitro activity against human immunodeficiency virus types 1 and 2, in the mouse and dog.
Supko JG; Malspeis L
Antimicrob Agents Chemother; 1995 Jan; 39(1):9-14. PubMed ID: 7695336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
